SecBot SecBot
PRESS-RELEASE ·Filed Mar 3, 2026

PASG

Passage Bio
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming interim safety and biomarker data from upliFT-D in 1H 2026, which could serve as a near-term catalyst; the improved cash position reduces near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.00
T+0 close · Mar 3, 2026 · via day close
Latest settled
−31.00%
T+60 · $5.52
Vs SPY
−41.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $8.00entry
  2. T+1 · 9mo ago +5.50%α +4.74% · $8.44
  3. T+5 · 8mo ago +6.38%α +6.85% · $8.51
  4. T+20 · 8mo ago −1.88%α +2.53% · $7.85
  5. T+60 · 6mo ago −31.00%α −41.32% · $5.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio reported Q4 and full-year 2025 financial results, highlighting clinical progress in its upliFT-D trial for frontotemporal dementia, including enrollment in new cohorts and a cash runway extending into Q1 2027. While R&D and net loss decreased year-over-year, no revenue was generated as the company remains pre-revenue with ongoing clinical development.

Key Financial Metrics

EPS
$-14.35

Key Facts

  • Cash and cash equivalents were $46.3 million as of December 31, 2025, down from $76.8 million in 2024.
  • R&D expenses decreased to $23.3 million in 2025 from $40.2 million in 2024.
  • Net loss narrowed to $45.5 million in 2025 from $64.8 million in 2024.
  • Enrolled first three FTD-GRN patients in Cohort 3 and treated first FTD-C9orf72 patient in Cohort 4 of the upliFT-D study.
  • Cash runway expected through Q1 2027.

Financial Impact

Reduced cash burn with R&D down 42% YoY and net loss reduced by $19.3 million, improving financial sustainability.

cashr_d_expensesnet_loss

Risk Factors

  • Clinical trial setbacks or adverse safety events could negatively impact valuation.
  • No revenue generation expected for several years as company remains in clinical development phase.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248197

Track record

15 reports on PASG

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026